---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-093553"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2023-08-18T23:59:59+00:00"
generated_at: "2026-06-11T06:53:33.875194+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Iovance reports LN-145 + pembrolizumab 42.1% ORR in ICI-naïve mNSCLC trial

## Summary
- ORR of 42.1% in ICI-naïve mNSCLC; 80% in treatment-naïve, 42.9% post-chemo, 14.3% EGFR-mutated post-TKI.
- Tumor burden reduction in 76.5% of patients; durable responses deepening over time up to 15.4 months.
- No new safety signals; TEAEs consistent with NMA-LD and IL-2 regimen.
- Results support phase 3 study design for LN-145 in front-line mNSCLC.
- Cash ~$478M (post-July offering) funds into end 2024; BLA filed for lifileucel in melanoma.

## SEC filing metadata
- accession: 0001104659-23-093553
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2023-08-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465923093553/0001104659-23-093553-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465923093553/tm2324118d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-093553
- JSON: https://secwatch.observer/filing/0001104659-23-093553.json
- Plain text: https://secwatch.observer/filing/0001104659-23-093553.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.